Raymond James Initiates Coverage on Integer (NYSE:ITGR)

Analysts at Raymond James initiated coverage on shares of Integer (NYSE:ITGR) in a report released on Friday,Benzinga reports. The brokerage set an “outperform” rating and a $145.00 price target on the medical equipment provider’s stock. Raymond James’ price objective suggests a potential upside of 23.15% from the company’s previous close.

Other research analysts also recently issued research reports about the company. Wells Fargo & Company reissued an “overweight” rating and issued a $160.00 target price on shares of Integer in a report on Tuesday, December 3rd. Truist Financial increased their price objective on shares of Integer from $147.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Benchmark boosted their target price on shares of Integer from $140.00 to $150.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Citigroup increased their price target on shares of Integer from $130.00 to $145.00 and gave the stock a “neutral” rating in a research report on Wednesday, December 11th. Finally, Oppenheimer lowered Integer from an “outperform” rating to a “market perform” rating in a research note on Friday, February 21st. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Integer currently has an average rating of “Moderate Buy” and an average price target of $148.56.

Integer Price Performance

NYSE ITGR opened at $117.74 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.09 and a current ratio of 2.95. The company has a market capitalization of $3.96 billion, a price-to-earnings ratio of 35.04, a PEG ratio of 1.72 and a beta of 1.24. The stock has a 50-day moving average of $130.95 and a 200 day moving average of $132.02. Integer has a one year low of $107.11 and a one year high of $146.36.

Integer (NYSE:ITGR) last issued its quarterly earnings data on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). Integer had a net margin of 6.92% and a return on equity of 11.65%. The company had revenue of $449.50 million for the quarter, compared to the consensus estimate of $446.28 million. On average, sell-side analysts forecast that Integer will post 6.01 EPS for the current year.

Institutional Trading of Integer

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mather Group LLC. grew its holdings in Integer by 304.3% during the 4th quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 143 shares in the last quarter. Lee Danner & Bass Inc. purchased a new position in Integer during the fourth quarter valued at $27,000. R Squared Ltd purchased a new stake in Integer in the 4th quarter worth $44,000. Sterling Capital Management LLC boosted its holdings in shares of Integer by 472.9% during the 4th quarter. Sterling Capital Management LLC now owns 338 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 279 shares during the last quarter. Finally, Versant Capital Management Inc grew its position in shares of Integer by 98.4% during the fourth quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider’s stock valued at $49,000 after purchasing an additional 183 shares in the last quarter. Institutional investors own 99.29% of the company’s stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.